Treatment of virus infections with ganglionic blocking agents
AssigneeBaltech, Inc.
InventorJoseph A. Baldone
Life of this patent
Estimating the term…
Abstract
A method for preventing or treating infection or disease in a mammal caused by a virus, such as herpes simplex virus type 1 and 2. A ganglionic blocking agent, such as tetraethylammonium ion or hexamethonium ions, is administered to the mammal in an effective dosage.
Claims17
A method of treating a mammalian disease caused by a DNA virus comprising the step of administering to the mammal a ganglionic blocking agent selected from the group consisting of tetraethylammonium ion, hexamethonium ion, pentolinium ion, chlorisondamine ion, trimethidinium ion, trimethaphan ion, mecamylamine, pempidine, and homologs thereof in an effective dosage, with the proviso that when the DNA virus is herpes zoster the ganglionic blocking agent is not tetraethylammonium chloride.
A method of treating a mammalian disease caused by a DNA virus comprising the step of administering to the mammal a ganglionic blocking agent selected from the group consisting of tetraethylammonium ion, hexamethonium ion, pentolinium ion, chlorisondamine ion, trimethidinium ion, trimethaphan ion, mecamylamine, pempidine, and homologs thereof in a dosage effective to produce an anti-viral effect with respect to a DNA virus, with the proviso that when the DNA virus is herpes zoster the ganglionic blocking agent is not tetraethylammonium chloride.
A method of treating a mammalian disease caused by a DNA virus comprising the step of administering to the mammal a ganglionic blocking agent selected from the group consisting of tetraethylammonium ion, hexamethonium ion, pentolinium ion, chlorisondamine ion, trimethidinium ion, trimethaphan ion, mecamylamine, pempidine, and homologs thereof in a dosage effective to inhibit the viral function of a DNA virus, with the proviso that when the DNA virus is herpes zoster the ganglionic blocking agent is not tetraethylammonium chloride.
A method of treating a mammalian disease caused by a Papovavirus, comprising administering to the mammal a ganglionic blocking agent selected from the group consisting of tetraethylammonium ion, hexamethonium ion, pentolinium ion, chlorisondamine ion, trimethidinium ion, trimethaphan ion, mecamylamine, pempidine, and homologs thereof in an effective dosage.
A method of treating a mammalian disease caused by a Cytomegalovirus, comprising administering to the mammal a ganglionic blocking agent selected from the group consisting of tetraethylammonium ion, hexamethonium ion, pentolinium ion, chlorisondamine ion, trimethidinium ion, trimethaphan ion, mecamylamine, pempidine, and homologs thereof in an effective dosage.
Dependencies are inferred from the claim text.